Tandem Diabetes Care Inc (TNDM) stock
Close on Nov 16, 2026Market cap $1.29BP/E –Yield –
Tandem Diabetes Care Inc grew revenue 4.0% to $1.04B over the twelve months to Jun 30, 2026. Free cash flow was -$26.62M. At the latest close the market valued the company at $1.29B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.29B
- P/E ratio
- –
- Price to sales
- 1.23
- Price to book
- 9.86
- Dividend yield
- –
- Free cash flow yield
- -2.07%
Fundamentals
- Revenue
- $1.04B
- Net income
- -$63.32M
- EPS, diluted
- -$0.93
- Free cash flow
- -$26.62M
- Book value per share
- $1.89
- Diluted shares
- 69M
Trading
- Next earnings
- Feb 18, 2027 (estimated, during market hours)
- Previous close
- $20.07
- Open
- $19.77
- Day's range
- $18.45 – $20.15
- Volume
- 2,668,313
- Average volume (20 days)
- 2,803,129
- Index membership
- S&P SmallCap 600 (since May 2023), Russell 2000 (since Sep 2024), Russell 3000
- 52-week range
- $12.26 – $29.65
- RSI (14 days)
- 51.8
- Volatility (1 year)
- 76.0%
- Relative volume
- 1.22×
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | TNDM | S&P 500 | Difference | TNDM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +13.8% | -3.1% | +16.8 pts | ||
| 3 months | -18.7% | -4.5% | −14.2 pts | ||
| Year to date | -15.9% | +9.4% | −25.3 pts | ||
| 1 year | -0.7% | +11.3% | −12.0 pts | ||
| 3 years | +0.4% | +70.4% | −70.0 pts | +0.1% | +19.4% |
| 5 years | -87.0% | +68.6% | −155.6 pts | -33.5% | +11.0% |
| 10 years | -7.6% | +297.7% | −305.3 pts | -0.8% | +14.8% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tandem Diabetes Care filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- News
- News
- Results
About Tandem Diabetes Care
Surgical & Medical Instruments & Apparatus
Tandem Diabetes Care, Inc. develops, manufactures, and sells medical devices and digital tools for diabetes management. The company primarily produces durable insulin pump systems, notably the t:slim X2 and Tandem Mobi, which incorporate its Control-IQ+ automated insulin delivery technology. It also provides disposable supplies, such as insulin cartridges and infusion sets, along with software applications including the Tandem Source data management platform and the Sugarmate mobile app. These products serve individuals with insulin-dependent diabetes, including people with type 1 diabetes and individuals with type 2 diabetes requiring intensive insulin therapy.
Company profile, executives and historyTandem Diabetes Care stock: common questions
What is Tandem Diabetes Care's stock price?
TNDM closed at $18.48 on Nov 16, 2026, down 7.92% on the day. Over the past 52 weeks it traded between $12.26 and $29.65.
What is Tandem Diabetes Care's market cap?
Tandem Diabetes Care was worth $1.29B at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is TNDM's P/E ratio?
Tandem Diabetes Care lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.93), so it has no meaningful P/E ratio.
How much revenue does Tandem Diabetes Care make?
Tandem Diabetes Care reported revenue of $1.04B for the twelve months to Jun 30, 2026, up 4.0% from a year earlier.
Does Tandem Diabetes Care pay a dividend?
No. Tandem Diabetes Care has not paid a cash dividend over the last twelve months.
When does Tandem Diabetes Care report earnings next?
Tandem Diabetes Care is expected to report Q4 FY2026 results on Feb 18, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has TNDM stock performed over the past year?
Including dividends, TNDM returned -0.7% over the past year, against +11.3% for the S&P 500.
How many TNDM shares are sold short?
16M shares were sold short at the latest FINRA report, 23.52% of the float, or 7.6 days of average trading volume.
Who are Tandem Diabetes Care's competitors?
Companies most similar to Tandem Diabetes Care by business, industry and size include MMED, PODD, EMBC, ICUI, DXCM.
See a number that looks wrong?